Open access · CC-BY
via OpenAlex
Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain
Martina P. Morawe, Fan Liao, Willi Amberg, Jeroen van Bergeijk, Rui Chang, Mary Gulino, Caitlin Hamilton, Carolin Hoft, Casey J. Lumpkin, Bryan Mastis, Emily J. McGlame, Judith Nuber, Christian Plaas, Brinda Ravikumar, Kaushambi Roy
European Journal of Pharmacology · 2022 · ▲ 20 citations
Abstract
In this study we aimed to reduce tau pathology, a hallmark of Alzheimer's Disease (AD), by activating mTOR(definition)-dependent autophagy(definition) in a transgenic mouse model of tauopathy by long-term dosing of animals with mTOR-inhibitors. Rapamycin(definition) treatment reduced the burden of hyperphosphorylated and aggregated pathological tau in the cerebral cortex only when applied to young mice, prior to the emergence of pathology. Conversely, PQR530 which exhibits better brain exposure and superior pharmacokinetic properties, reduced tau pathology even when the treatment started after the onset of pathology. Our results show that dosing animals twice per week with PQR530 resulted in intermittent, rather than sustained target engagement. Nevertheless, this pulse-like mTOR inhibition followed by longer intervals of re-activation was sufficient to reduce tau pathology in the cerebral cortex in P301S tau transgenic mice. This suggests that balanced therapeutic dosing of blood-brain-barrier permeable mTOR-inhibitors can result in a disease-modifying effect in AD and at the same time prevents toxic side effects due to prolonged over activation of autophagy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.ejphar.2022.175301
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Morawe, M.P., Liao, F., Amberg, W., Bergeijk, J.V., Chang, R., Gulino, M., Hamilton, C., Hoft, C., Lumpkin, C.J., Mastis, B., McGlame, E.J., Nuber, J., Plaas, C., Ravikumar, B., Roy, K., Schanzenbächer, M., Tierno, J., Lakics, V., Dellovade, T., & Townsend, M. (2022). Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain. <em>European Journal of Pharmacology</em>. https://doi.org/10.1016/j.ejphar.2022.175301
Vancouver
Morawe MP, Liao F, Amberg W, Bergeijk JV, Chang R, Gulino M, et al. Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain. European Journal of Pharmacology. 2022. doi:10.1016/j.ejphar.2022.175301.
BibTeX
@article{martina2022Pharma,
title = {Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain},
author = {Martina P. Morawe and Fan Liao and Willi Amberg and Jeroen van Bergeijk and Rui Chang and Mary Gulino and Caitlin Hamilton and Carolin Hoft and Casey J. Lumpkin and Bryan Mastis and Emily J. McGlame and Judith Nuber and Christian Plaas and Brinda Ravikumar and Kaushambi Roy and Marion Schanzenbächer and Joseph Tierno and Viktor Lakics and Tammy Dellovade and Matthew Townsend},
journal = {European Journal of Pharmacology},
year = {2022},
doi = {10.1016/j.ejphar.2022.175301},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Alzheimer s Disease 2013
Open access · OA
Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy
Journal of Alzheimer s Disease 2024
Preprint · OA
Senescence Targeting Methods Impact Alzheimer’s Disease Features in 3xTg Mice
NeuroImage 2026
Citation only
Adaptive Gaussian graph-spectral filtering for scale-specific connectivity inference.
Molecular Neurodegeneration 2016
Open access · CC-BY
Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy
Biochimica et Biophysica Acta (BBA) - Biomembranes 2018
Open access · OA
Impact of membrane curvature on amyloid aggregation
Autophagy 2023
Preprint · OA